Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 8—August 2025
Dispatch
Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016–2023
, Jeremy A.W. Gold, Kaitlin Forsberg, Sophie Jones, and Meghan M. Lyman
Table 2
Patients with Candida auris screening cases with progression to clinical case status, by body site of clinical case detection, United States, 2016–2023*
| Characteristic | All, N = 1,458 | Blood, n = 584 | Urine, n = 391 | Respiratory, n = 233 | Wound, n = 168 | Other, n = 82† | p value‡ |
|---|---|---|---|---|---|---|---|
| Median age at collection of screening case specimen, y (IQR), n = 1,238 |
67 (59–76) |
68 (60–76) |
68 (58–77) |
68 (60–77) |
67 (61–75) |
64 (50–71) |
0.023 |
| Age group at collection of screening case specimen, y, n = 1,238 | 0.027 | ||||||
| <45 | 118 | 42 (35.6) | 40 (33.9) | 8 (6.8) | 15 (12.7) | 13 (11.0) | |
| 45–54 | 105 | 35 (33.3) | 27 (25.7) | 21 (20.0) | 11 (10.5) | 11 (10.5) | |
| 55–64 | 279 | 106 (38.0) | 69 (24.7) | 55 (19.7) | 38 (13.6) | 11 (3.9) | |
| 65–74 | 368 | 134 (36.4) | 97 (26.4) | 68 (18.5) | 48 (13.0) | 21 (5.7) | |
| 75–84 | 274 | 106 (38.7) | 83 (30.3) | 43 (15.7) | 31 (11.3) | 11 (4.0) | |
| >85 |
94 |
33 (35.1) |
26 (27.7) |
22 (23.4) |
12 (12.8) |
1 (1.1) |
|
| Sex, n = 1,183 | <0.001 | ||||||
| M | 671 | 215 (32.0) | 216 (32.2) | 124 (18.5) | 76 (11.3) | 40 (6.0) | |
| F |
512 |
218 (42.6) |
110 (21.5) |
84 (16.4) |
73 (14.3) |
27 (5.3) |
|
| Antimicrobial Resistance Laboratory Network region of the facility of specimen collection for clinical case§ | <0.001 | ||||||
| West | 898 | 306 (34.1) | 252 (28.1) | 173 (19.3) | 124 (13.8) | 43 (4.8) | |
| Midwest | 96 | 24 (25.0) | 36 (37.5) | 22 (22.9) | 8 (8.3) | 6 (6.3) | |
| Southeast | 56 | 33 (58.9) | 10 (17.9) | 7 (12.5) | 3 (5.4) | 3 (5.4) | |
| Northeast | 302 | 177 (58.6) | 68 (22.5) | 25 (8.3) | 20 (6.6) | 12 (4.0) | |
| Mid-Atlantic | 64 | 37 (57.8) | 11 (17.2) | 3 (4.7) | 4 (6.3) | 9 (14.1) | |
| Mountain | 42 | 7 (16.7) | 14 (33.3) | 3 (7.1) | 9 (21.4) | 9 (21.4) | |
| Central¶ |
0 |
0 (NA) |
0 (NA) |
0 (NA) |
0 (NA) |
0 (NA) |
|
| No. days from collection date of first positive screening to first clinical case specimen# | 0.001 | ||||||
| Median (IQR) | 46 (19–108) | 58 (22–130) | 44 (20–120) | 33 (17–74) | 44 (17–91) | 28 (14–77) | |
| Minimum–maximum | 1–1,597 | 1–1,309 | 1–1,597 | 1–1,240 | 1–666 | 1–745 | |
*Values are no. (%) except as indicated. IQR, interquartile range. †Other specimen type included device (n = 14), fluid/drainage (n = 5), intraabdominal (n = 2), other (n = 60), and unknown (n = 1). ‡p values were calculated using χ2 tests (categorical variables) or Kruskal-Wallis rank-sum test (continuous variables) to compare features of interest by body site. §https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/domestic.html. Data from 2023 were unavailable from one state in the Central region. ¶Row excluded from p value calculations because no screening-to-clinical cases were reported in the Central region. #Data missing for 1 patient with a clinical case involving a wound.